… we deepened research on the molecular mechanisms underlying anti-angiogenic strategies
… effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies. …

… The mechanism of drug resistance of vessel co-option is that anti-angiogenic drugs currently
used can only target the new vessels produced by the combination of angiogenic factors …

… Also, the rate of progression varies widely across individual patients. Accordingly, not only
are there unanswered questions regarding what type of treatment should be administered …

… The aim of this paper was to review the evidence for anti-angiogenic therapy in cancer
therapeutics and the mechanisms and management of tumour resistance to antiangiogenic …

… from a specific anti-angiogenic treatment, compared to those who will develop resistance
and/or adverse effects. Indeed, the response to anti-angiogenic therapy is characterized by …

… Below, we discuss the role of vessel co-option in resistance to anti-angiogenic therapy in
different tumour types and the potential consequences for the future of anti-cancer therapy. …

… resistance to antiangiogenic therapies. The present review summarizes the current status
of … Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat …

… of new targeted anti-angiogenic therapies in PC. These could include the identification of
specific subsets of patients who might benefit from these therapeutic … on anti-angiogenic agents …

… In the following content, we will describe the role of pro-angiogenic and anti-angiogenic …
Therefore, combination therapy as the future direction of antiangiogenic therapy seems to be …

… It has been shown that tumor vasculogenesis and progression after anti-angiogenic therapies
(AATs) and anti-autophagic therapies are due to cross-talk between endothelial and tumor …